FOLT方案与SOX方案治疗局部晚期胃癌的疗效和安全性及对血清TAM、DKK-1影响的对比

Comparison of the efficacy and safety of FOLT regimen and SOX regimen in the treatment of locally advanced gastric cancer and their effects on serum TAM and DKK-1

[目的]研究胃癌新辅助化疗方案(FLOT方案)与S-1+奥沙利铂方案(SOX方案)治疗局部晚期胃癌的疗效和安全性对比及对血清肿瘤相关物质(TAM)、分泌型糖蛋白(DKK-1)的影响。[方法]选取78例局部晚期胃癌患者,随机分为对照组(38例)和观察组(40例)。对照组患者给予SOX方案化疗,观察组患者给予FOLT方案化疗。评估患者临床疗效;采用酶联免疫双抗夹心法检测血清中TAM、癌胚抗原(CEA)和DKK-1水平;记录2组患者中位生存时间及患者安全性。[结果]观察组、对照组患者临床治疗总有效率分别为87.50%、68.42%,组间比较差异有统计学意义(P<0.05)。治疗前,对照组与观察组患者血清TAM、CEA和DKK-1水平相当(P>0.05);治疗后,2组患者血清TAM、CEA和DKK-1水平均降低,且观察组降低幅度更大(P<0.05)。观察组患者中位生存时间为13.00个月(95%CI:11.73~13.48个月),对照组患者中位生存时间为9.00个月(95%CI:7.89~9.75个月),观察组患者中位生存期显著长于对照组,组间比较差异有统计学意义(P<0.05)。对照组和观察组患者不良反应比较差异无统计学意义(P>0.05)。[结论]FOLT方案对局部晚期胃癌的治疗效果优于SOX方案,可以显著降低患者血清TAM、CEA和DKK-1水平,提高患者中位生存期,且不良反应在可接受范围内。

[Objective]To study the comparison of the efficacy and safety of FOLT regimen and SOX regimen in the treatment of locally advanced gastric cancer and the effect on serum tumor-related substances(TAM)and Dickkopf-1(DKK-1).[Methods]A total of 78 locally advanced gastric cancer patients admitted to our hospital from February 2019 to January 2021 were selected and randomly divided into a control group(38 cases)and an observation group(40 cases).Patients in the control group were given SOX regimen chemotherapy, and patients in the observation group were given FOLT regimen chemotherapy.Assess the clinical efficacy of patients.Enzyme-linked immunological double-antibody sandwich method was used to detect serum levels of TAM,carcinoembryonic antigen(CEA)and DKK-1.The median survival time of the two groups of patients and the safety of the two groups of patients were recorded.[Results]The effective rates of clinical treatment in the observation group and the control group were 87.50% and 68.42%,respectively, and the difference between the groups was statistically significant(P<0.05).Before treatment, the serum TAM,CEA and DKK-1 levels of the control group and the observation group were the same(P>0.05).After treatment, the serum TAM,CEA and DKK-1 levels of the two groups of patients decreased, and the decrease in the observation group was even greater(P<0.05).The median survival time of patients in the observation group was 13.00 months(95%CI:11.73-13.48 months),and the median survival time of patients in the control group was 9.00 months(95%CI:7.89-9.75 months).The survival time was significantly longer than that of the control group, and the difference between the groups was significant(P<0.05).The difference in adverse reactions between the control group and the observation group was not statistically significant(P>0.05).[Conclusion]The FOLT regimen is better than the SOX regimen in the treatment of locally advanced gastric cancer.It can significantly reduce the patient’s serum TAM,CEA and DKK-1 levels, improve the patient’s median survival, and the adverse reactions are within an acceptable range.